Abstract
Breast cancer is the second-leading cause of cancer death among women in the United States, alone. Many papers throughout the past and current medical literature have shown it is strongly associated with the reproductive axis and the growth hormone axis. Ghrelin is a pleiotropic 28-aminoacidic hormone and an integrated component of the GH axis, which is implicated in breast cancer risk factors. There has never been published a systematic review about ghrelin, its receptor and gene and their relation to breast cancer till this day, to our knowledge. The main goal of this systematic review is to explore the aforementioned relationship in perspective to new therapeutic targets. A systematic review of relevant studies by searching the PubMed and the SciVerse Scopus databases was performed retrieving four (4) experimental studies, three (3) cohort and one (1) case-control study, which were included in the present systematic review, out of 63 papers. Ghrelin is definitely an auspicious candidate molecule for breast cancer prevention, detection and therapy. Future studies should be encouraged to investigate ghrelin axis on breast cancer pathogenesis and/or tumorigenesis, which hopefully would give results in difficult breast cancer cases, such as in reproductive females.
Keywords: Ghrelin, breast cancer, novel therapeutic targets, hormonal levels, pathophysiologic mechanisms, 28-aminoacidic hormone, mammography, progesterone, oestrogen, pathogenesis
Current Signal Transduction Therapy
Title:The Role of Ghrelin Signals in Breast Cancer- A Systematic Review
Volume: 7 Issue: 3
Author(s): Charikleia Stefanaki, Filippos-Paschalis Rorris and Michael Stamatakos
Affiliation:
Keywords: Ghrelin, breast cancer, novel therapeutic targets, hormonal levels, pathophysiologic mechanisms, 28-aminoacidic hormone, mammography, progesterone, oestrogen, pathogenesis
Abstract: Breast cancer is the second-leading cause of cancer death among women in the United States, alone. Many papers throughout the past and current medical literature have shown it is strongly associated with the reproductive axis and the growth hormone axis. Ghrelin is a pleiotropic 28-aminoacidic hormone and an integrated component of the GH axis, which is implicated in breast cancer risk factors. There has never been published a systematic review about ghrelin, its receptor and gene and their relation to breast cancer till this day, to our knowledge. The main goal of this systematic review is to explore the aforementioned relationship in perspective to new therapeutic targets. A systematic review of relevant studies by searching the PubMed and the SciVerse Scopus databases was performed retrieving four (4) experimental studies, three (3) cohort and one (1) case-control study, which were included in the present systematic review, out of 63 papers. Ghrelin is definitely an auspicious candidate molecule for breast cancer prevention, detection and therapy. Future studies should be encouraged to investigate ghrelin axis on breast cancer pathogenesis and/or tumorigenesis, which hopefully would give results in difficult breast cancer cases, such as in reproductive females.
Export Options
About this article
Cite this article as:
Stefanaki Charikleia, Rorris Filippos-Paschalis and Stamatakos Michael, The Role of Ghrelin Signals in Breast Cancer- A Systematic Review, Current Signal Transduction Therapy 2012; 7 (3) . https://dx.doi.org/10.2174/157436212802481547
DOI https://dx.doi.org/10.2174/157436212802481547 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Food Applications for Flaxseed and its Components: Products and Processing
Recent Patents on Food, Nutrition & Agriculture Cytotoxic Thiol Alkylators
Mini-Reviews in Medicinal Chemistry 1,3,4-Oxadiazole Derivatives as Potential Biological Agents
Mini-Reviews in Medicinal Chemistry Analysis of Oxaliplatin Resistance in Colorectal Cancer Cells by Combined Proteomics and Phosphoproteomic
Current Proteomics Retroviral Gene Therapy: Safety Issues and Possible Solutions
Current Gene Therapy Blockers of Voltage-Gated Sodium Channels for the Treatment of Central Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics
Current Drug Metabolism Phytoestrogens: Implications in Neurovascular Research
Current Neurovascular Research Fluorine-18 Labeled Amino Acids for Oncologic Imaging with Positron Emission Tomography
Current Topics in Medicinal Chemistry PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets Cytokines in HIV-Infection - Inflammatory Damage or Therapeutic Potential?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Fluorescence Imaging in Cancerology
Current Molecular Imaging (Discontinued) Signaling Through Rho GTPase Pathway as Viable Drug Target
Current Medicinal Chemistry Oleamide Derivatives are Prototypical Anti-Metastasis Drugs that Act by Inhibiting Connexin 26
Current Drug Safety Stroke Induced Immunodepression Syndrome: From Bench to Bedside
Current Molecular Medicine Emerging Evidence for Neurotensin Receptor 1 Antagonists as Novel Pharmaceutics in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design Dietary Polyphenols for Prostate Cancer Therapy
Current Bioactive Compounds Rapid Desensitization of Hypersensitivity Reactions to Chemotherapy Agents.
Current Drug Safety